Market Overview - The Hong Kong stock market experienced its first decline of the year on January 7, with the Hang Seng Index closing at 26,458.95 points, down 251.50 points, a decrease of 0.94% [1][2]. - The Hang Seng Tech Index also fell, closing at 5,738.52 points, down 86.74 points, a decline of 1.49% [2]. Sector Performance - The pharmaceutical and biotechnology sector saw significant gains, with Rongchang Biologics (HK09995) rising over 12%, and other companies like Kailaiying (HK06821) and Tigermed (HK03347) increasing by over 8% [5]. - Rongchang Biologics announced positive clinical trial data for its PD-1/VEGF bispecific antibody RC148, which showed promising efficacy and safety for treating non-small cell lung cancer [5]. - Kangfang Biologics received approval for an important update on its PD-1/VEGF bispecific antibody, indicating significant clinical benefits in treating advanced non-small cell lung cancer [7]. Investment Trends - Southbound funds continued to significantly increase their holdings in Hong Kong stocks, with a net purchase exceeding 9.1 billion HKD by the end of the trading day [8]. - Research from CICC suggests that the Hong Kong stock market is entering a recovery phase, driven by a weaker US dollar and improved domestic liquidity, with a positive outlook for the first half of 2026 [12]. - Guotai Junan Securities anticipates a second round of valuation recovery and performance resurgence in the Hong Kong market in 2026, recommending focus on technology, healthcare, and consumer sectors [12]. Analyst Ratings - Credit Lyonnais maintained a "Outperform" rating for WuXi AppTec, raising the target price to 143.4 HKD, citing expected growth from outsourcing demand and reduced policy uncertainty [10].

Market Overview - The Hong Kong stock market indices experienced a decline, with the Hang Seng Index falling by 1.01% to 26,439.68 points, the Hang Seng Tech Index down by 1.65%, and the National Enterprises Index decreasing by 1.11% [1][9]. Technology Sector - Technology stocks faced widespread losses, with Alibaba dropping over 4%, Bilibili down more than 3%, and Kuaishou, NetEase, and Meituan each declining by over 2% [1][9]. Biopharmaceutical Sector - The biopharmaceutical sector continued its upward trend, highlighted by Kangfang Biopharmaceutical's stock rising over 6%. The company announced an important update regarding its PD-1/VEGF bispecific antibody, which has shown statistically significant and clinically meaningful benefits in treating advanced non-squamous non-small cell lung cancer [2][11]. Metals Sector - The metals sector showed strength, with Luoyang Molybdenum rising over 5%. Citigroup raised its short-term copper price target to $14,000 per ton, although it warned that the price increase may be nearing its peak [5][14]. Oil Sector - Oil stocks weakened, with PetroChina falling over 3%. This decline follows an announcement regarding the transfer of 30 to 50 million barrels of oil from the Venezuelan interim government to the U.S., which will be sold at market prices [5][16]. Automotive Sector - The automotive sector saw significant declines, with NIO dropping over 3%. Reports indicate that the Chinese auto market may experience a 7% decline in sales in 2026, marking the first anticipated annual drop since 2020. A price war has begun, involving over 76 models from various manufacturers [6][16].

Core Viewpoint - Kangfang Biopharma (09926) experienced a significant stock increase of 6.15%, reaching HKD 127.8, with a trading volume of HKD 789 million, following the approval of an important update to the product label of its innovative PD-1/VEGF bispecific antibody, Ivosidenib (brand name: Yidafang) by the National Medical Products Administration [1] Group 1 - The update includes final analysis data from the AK112-301/HARMONi-A study, demonstrating statistically significant and clinically meaningful dual benefits in progression-free survival (PFS) and overall survival (OS) for Ivosidenib in treating locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC) after progression on EGFR-TKI therapy [1] - The HARMONi-A study is noted as the first global Phase III clinical trial in the EGFR-TKI resistant nsq-NSCLC treatment field to achieve clinically meaningful and statistically significant benefits in both PFS and OS endpoints [1] - This trial is also recognized as the first randomized, double-blind Phase III clinical trial to achieve dual positive results in both PFS and OS, reaffirming the groundbreaking clinical value of Ivosidenib as the world's first tumor immune + anti-angiogenesis mechanism bispecific antibody [1]

Core Viewpoint - Kangfang Biopharma (09926) has seen a stock increase of over 6%, currently trading at 127.8 HKD with a transaction volume of 789 million HKD, following the approval of a significant update to the product label of its innovative PD-1/VEGF bispecific antibody, Ivosidenib (brand name: Yidafang) by the National Medical Products Administration [1] Group 1 - The update includes final analysis data from the AK112-301/HARMONi-A study, demonstrating statistically significant and clinically meaningful dual benefits in progression-free survival (PFS) and overall survival (OS) for Ivosidenib in treating locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC) after progression on EGFR-TKI therapy [1] - The HARMONi-A study is the first global Phase III clinical trial in the EGFR-TKI resistant nsq-NSCLC treatment field to achieve clinically meaningful and statistically significant benefits in both PFS and OS endpoints [1] - This trial is also the first randomized, double-blind Phase III clinical trial to achieve dual positive results in PFS and OS, reaffirming the groundbreaking clinical value of Ivosidenib as the world's first tumor immune + anti-angiogenesis mechanism bispecific antibody [1]

Core Viewpoint - The biotechnology sector in Hong Kong is experiencing growth potential due to policy support and strong demand, with innovative pharmaceutical companies leading the way in research and development [1] Group 1: Market Performance - On January 7, the Shanghai and Shenzhen markets showed mixed performance with slight fluctuations, while the communication, electronics, and comprehensive sectors led in gains [1] - The Hang Seng Biotechnology ETF (159615.SZ) rose by 2.82%, and Kangfang Biotech increased by 6.56% [1] Group 2: Industry Insights - Huatai Securities highlights that the biotechnology sector benefits from policy backing and has a robust pipeline of innovative drugs and high internationalization [1] - Global investment in biotechnology research and development continues to rise, indicating significant growth potential in sub-sectors like innovative drugs and medical devices [1] Group 3: Valuation and Economic Context - Current valuations of Hong Kong biotechnology companies are considered attractive, with expectations for industry prosperity to increase under supportive policies [1] - The technology sector in Hong Kong has faced valuation pressures due to factors like U.S. Federal Reserve interest rate hikes, but with stabilizing U.S. ten-year Treasury yields, there is an increasing expectation for liquidity improvement and valuation recovery [1] - The positive trend in China's economic recovery and ongoing policy support in the technology sector provide a solid fundamental basis for the Hong Kong technology sector [1] Group 4: Investment Value - The Hang Seng Biotechnology ETF (159615.SZ) serves as a key investment tool for the Hong Kong biotechnology sector, closely tracking the sector and covering areas such as innovative drugs and medical devices, thus presenting good investment value [1]

Group 1: Market Performance - Hong Kong's innovative drug ETF (159570) surged by 3%, with a trading volume exceeding 1.5 billion yuan, following a net inflow of over 62 million yuan today after a previous inflow of 430 million yuan [1][3] - As of January 6, the latest scale of the Hong Kong innovative drug ETF reached over 23.3 billion yuan, leading its peers in the same category [1] Group 2: Economic Signals - Federal Reserve Governor Milan indicated that upcoming economic data may support further interest rate cuts, with expectations of a reduction exceeding 100 basis points this year [3] - Wall Street analysts suggest that if the U.S. unemployment rate rises to 4.7% by December 2025, the Fed may cut rates by 25 basis points this month [3] Group 3: Company Developments - Brain-computer interface "unicorn" Strong Brain Technology completed a financing round of 2 billion yuan, second only to Musk's Neuralink [3] - AI pharmaceutical company Insilico Medicine announced a long-term collaboration with Siveya for anti-tumor drug development, with a total deal value of 888 million USD [3] Group 4: New Drug Approvals - On January 6, BeiGene announced that its self-developed BCL2 inhibitor, Baiyueda® (sotucumab), received conditional approval from the National Medical Products Administration [3] - Shiyao's SYS6017 has initiated Phase II clinical trials for the prevention of shingles [3] Group 5: Investment Insights - Zhongtai Securities predicts that the pharmaceutical sector's opportunities in 2025 will focus on innovation and industry upgrades, with investment strategies continuing into 2026 [5] - The report emphasizes the importance of "innovative drugs and industry chains, demand recovery, and AI" as key investment dimensions [5] Group 6: J.P. Morgan Healthcare Conference - The 44th J.P. Morgan Healthcare Conference is set to take place from January 12 to 15, 2026, in San Francisco, attracting over 8,000 global participants [6] - The conference will feature over 500 listed companies and thousands of startups, focusing on "capital + strategy" discussions [6] Group 7: Industry Trends - Three major trends are highlighted for 2026: the continued rise of gene and cell therapies, deep integration of AI in pharmaceuticals, and the emergence of new market forces [7] - The report notes that over 20 gene editing companies will showcase breakthroughs in CAR-T and base editing at the conference [7] Group 8: MNC Engagement - Multinational corporations (MNCs) are willing to pay higher prices for innovative drugs from China, with the average total package for drugs purchased from China being 2.76 billion USD, compared to 1.29 billion USD for those from overseas [8] - The willingness of MNCs to pay a premium for Chinese innovations is driven by the need to fill significant pipeline gaps due to impending patent expirations [8] Group 9: Investment Focus - Investment strategies should focus on companies with strong clinical development capabilities and those in popular therapeutic areas such as ADCs, GLP-1, and dual antibodies [11] - Companies that can produce high-quality late-stage clinical assets are likely to attract MNC interest [11] Group 10: Key Therapeutic Areas - The report identifies key therapeutic areas for investment, including ADCs, GLP-1, dual antibodies, and neuroscience, emphasizing the need for innovative platforms and clinical data superiority [12]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09926 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,000 FF301 第 1 頁 共 10 頁 ...

Group 1 - The core point of the article highlights that in December 2025, the worst-performing ordinary equity and mixed funds were both managed by Baoying Fund, specifically the Baoying Medical Health Hong Kong-Shenzhen Stock A and C, which reported returns of -13.20% and -13.26% respectively [1] - The Baoying Innovation Medical Mixed Initiation A and C funds also performed poorly, with returns of -14.14% and -14.19%, making them the worst in the mixed fund category [1] - All these funds are themed around the medical sector and are managed by the same fund manager, Yao Yi, who has a background in research and fund management [1] Group 2 - The latest quarterly report indicates that the top ten holdings of the Baoying Medical Health Hong Kong-Shenzhen Stock fund include major companies such as Innovent Biologics, Kelun Pharmaceutical, and others, while the Baoying Innovation Medical Mixed Initiation fund shares many of the same top holdings [1][2] - Notably, several of these top holdings experienced significant declines in December, with the largest holding, Innovent Biologics, dropping by 18.97%, and another major holding, 3SBio, declining by over 22% [2] - The performance metrics of the funds show that the Baoying Innovation Medical Mixed Initiation C has a cumulative net value of 0.8857 and a scale of 0.51 billion, while the A share has a cumulative net value of 0.8886 and a scale of 0.47 billion [3]

Core Viewpoint - The Hong Kong Innovative Drug ETF (159567) has shown a positive performance since its inception, with a slight increase in scale and significant trading activity in the early days of 2024 [1][2] Group 1: Fund Performance - The Hong Kong Innovative Drug ETF (159567) closed at a 0.38% increase on January 6, with a trading volume of 1.163 billion yuan [1] - As of January 5, the fund's latest share count was 10.479 billion shares, with a total scale of 8.331 billion yuan, reflecting a 5.50% increase in scale since December 31, 2025 [1] - The fund's management fee is set at 0.50% annually, and the custody fee is 0.10% annually [1] Group 2: Trading Activity - Over the past 20 trading days, the cumulative trading amount for the ETF reached 16.464 billion yuan, with an average daily trading amount of 0.823 billion yuan [1] - In the first two trading days of 2024, the ETF recorded a cumulative trading amount of 2.789 billion yuan, averaging 1.394 billion yuan per day [1] Group 3: Fund Holdings - The top holdings of the Hong Kong Innovative Drug ETF include companies such as BeiGene, CanSino Biologics, and Innovent Biologics, with significant percentages of the fund's total assets allocated to these stocks [2] - The largest holding is BeiGene, accounting for 10.62% of the portfolio, followed closely by CanSino Biologics at 10.55% and Innovent Biologics at 10.21% [2] - Other notable holdings include China National Pharmaceutical Group and Stone Group, with respective allocations of 9.62% and 7.56% [2]

Group 1 - The core viewpoint of the report is that the Chinese biopharmaceutical sector experienced a comprehensive increase in 2025, and for 2026, a more selective stock-picking strategy is recommended, focusing on high-quality targets [1] Group 2 - Daiwa's top picks include Innovent Biologics and Hengrui Medicine, with Innovent's target price raised from HKD 95 to HKD 112, while Hengrui's target price remains at HKD 80 [1] - The rating for CanSino Biologics has been downgraded from "Buy" to "Hold," with its target price increased from HKD 100 to HKD 116 [1] - The rating for CSPC Pharmaceutical Group is maintained at "Sell," with a target price of HKD 6.6 [1]